• Mashup Score: 4
    New Biomarkers in Heart Failure: The Bar is High - 2 year(s) ago

    Soluble urokinase plasminogen activator receptor (suPAR) is the circulating form of uPAR, a glycosyl-phosphatidylinositol-anchored 3-domain receptor protein expressed on immune cells, and correlates with inflammatory states.1 Increased suPAR levels are associated with the progression of chronic kidney disease and cardiovascular disease (CVD), and are especially associated with poor outcomes in…

    Source: Journal of Cardiac Failure
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCardFail
      JCardFail

      Phenomenal editorial to contextualize: "New Biomarkers in Heart Failure: The Bar is High" @SarahHale321 @NMHheartdoc https://t.co/xbQEV6IvQb

  • Mashup Score: 1
    HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support - 2 year(s) ago

    The medical management of patients supported with durable continuous flow left ventricular assist device (LVAD) support encompasses pharmacologic therapies administered in the preoperative, intraoperative, postoperative and chronic LVAD support stages. As patients live longer on LVAD support, the risks of LVAD-related complications and progression of cardiovascular and other diseases increase….

    Source: Journal of Cardiac Failure
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HFSA
      HFSA

      New Consensus Statement released today by HFSA offers best practices on the medical management of patients on durable mechanical circulatory support, published in @JCardFail. @bhtrachtenberg @preventfailure 🔗https://t.co/6GqCZsxrPA 🔗https://t.co/EX4NRKWb2b https://t.co/lLZsP82iSy

  • Mashup Score: 13
    HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support - 2 year(s) ago

    The medical management of patients supported with durable continuous flow left ventricular assist device (LVAD) support encompasses pharmacologic therapies administered in the preoperative, intraoperative, postoperative and chronic LVAD support stages. As patients live longer on LVAD support, the risks of LVAD-related complications and progression of cardiovascular and other diseases increase….

    Source: Journal of Cardiac Failure
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCardFail
      JCardFail

      Hot off the press at JCF: HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support @preventfailure @Prof_J_NYC @RenzoLoyaga @rcogswell_umn @LiviuKlein @PalakShahMD @michaelkiernan @VorovichHeartMD https://t.co/8OAlglqLh4 https://t.co/D5rCMfiCW6

  • Mashup Score: 12
    Cultivating Interest in Heart Failure Careers: Can We Reverse the Current Trend? - 2 year(s) ago

    It is an exciting time to be a heart failure (HF) physician. After decades of stagnation in the development of effective treatments for HF, we are now enjoying a surge in new medical therapies, greater insights into pathophysiology, and extraordinary innovation in percutaneous and surgical interventions. However, simultaneously, the number of individuals living with and dying from HF continues to…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of noshreza
      noshreza

      Persistent themes on strategies to strengthen the AHFTC workforce #HFLeadership 👀 the ideas from @SarahChuzi and me in 2021 @JCardFail — reiterated tonight by @dranulala @AHajduczok @sonuabrahammd https://t.co/cC9EgoH0jA https://t.co/2giHriPaD8 https://t.co/69pUEHfi3E

  • Mashup Score: 8
    Incident Heart Failure With Mildly Reduced Ejection Fraction: Frequency, Characteristics, and Outcomes - 2 year(s) ago

    The classification of patients with heart failure (HF) according to ejection fraction (EF) is evolving.1 HF with an EF of 41%–49% was previously termed HF with borderline or midrange EF, but is now proposed to represent HF with mildly reduced EF (HFmrEF).2–4 This reclassification is critically important; post hoc analyses of clinical trials have suggested that patients with HFmrEF may derive…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of noshreza
      noshreza

      RT @JCardFail: ⭐️"Incident HFmrEF: Frequency, Characteristics, & Outcomes"⭐️ @VinayakKumarMD @ShannonMDunlay 👉https://t.co/VXgqdaBDJd Ed…

    • Profile photo of JCardFail
      JCardFail

      ⭐️"Incident HFmrEF: Frequency, Characteristics, & Outcomes"⭐️ @VinayakKumarMD @ShannonMDunlay 👉https://t.co/VXgqdaBDJd Editorial by @PeterEckmanMD & R Crespo: "Who wants the middle seat?: HFmrEF in a world dominated by HFpEF and HFrEF" 👉https://t.co/oxfXO9CYoI https://t.co/UQQl3kvmlw

  • Mashup Score: 3
    Lifting and Healing as We Climb: Women's Heart Month - 2 year(s) ago

    Once again this February, Heart Month prompts us to reflect on the core mission of promoting cardiovascular (CV) health, with special focus on the importance of heart health in women, who often are underdiagnosed, late to present, and less likely to receive appropriate treatment.1 The American Heart Association’s Go Red for Women campaign is focused on this mission and carries out activities…

    Source: Journal of Cardiac Failure
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AmitGoyalMD
      AmitGoyalMD

      RT @ersied727: Grateful to 🖊️ the February @JCardFail Editors Page with @dranulala @robmentz for 🫀Month! https://t.co/PRXAnjBdxo Looking…

Load More